Compare · EVMN vs NVS
EVMN vs NVS
Side-by-side comparison of Evommune Inc. (EVMN) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $287.12B, about 987.0x EVMN ($290.9M).
- EVMN has been more active in the news (24 items in the past 4 weeks vs 4 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 15 for EVMN).
- Company
- Evommune Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $290.9M
- $287.12B
- 1M return
- -
- -3.71%
- 1Y return
- -
- +18.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 24
- 4
- Recent ratings
- 15
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest EVMN
- Director Arthur S Kirsch returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Director David E Cohen returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Director Benjamin F Mcgraw III returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Chief of Dev. Operations Janice Suzann Drew returned 305,166 stock options to the company and was granted 305,166 stock options (SEC Form 4)
- Chief Scientific Officer Jeegar Pravinkumar Patel returned 248,934 stock options to the company and was granted 248,934 stock options (SEC Form 4)
- Chief Financial Officer Kyle Carver returned 378,354 stock options to the company and was granted 378,354 stock options (SEC Form 4)
- Chief Business & Legal Officer Gregory S. Moss returned 408,775 stock options to the company and was granted 408,775 stock options (SEC Form 4)
- Chief Medical Officer Eugene Bauer returned 151,117 stock options to the company and was granted 151,117 stock options (SEC Form 4)
- President & CEO Luis C. Pena returned 1,088,261 stock options to the company and was granted 1,088,261 stock options (SEC Form 4)
- SEC Form 424B3 filed by Evommune Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG